Dashboard
Manage Tickers

BIIBBIOGEN INC.

Nasdaq biogen.com


$ 208.98 $ 6.44 (3.18 %)    

Friday, 26-Apr-2024 15:59:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 208.9
$ 200.10
$ 0.00 x 0
$ 0.00 x 0
$ 200.10 - $ 210.81
$ 189.44 - $ 319.76
1,894,098
na
30.48B
$ 0.68
$ 26.13
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-24-2024 03-31-2024 10-Q
2 02-14-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 07-25-2023 06-30-2023 10-Q
5 04-25-2023 03-31-2023 10-Q
6 02-15-2023 12-31-2022 10-K
7 10-25-2022 09-30-2022 10-Q
8 07-20-2022 06-30-2022 10-Q
9 05-03-2022 03-31-2022 10-Q
10 02-03-2022 12-31-2021 10-K
11 10-20-2021 09-30-2021 10-Q
12 07-22-2021 06-30-2021 10-Q
13 04-22-2021 03-31-2021 10-Q
14 02-03-2021 12-31-2020 10-K
15 10-21-2020 09-30-2020 10-Q
16 07-22-2020 06-30-2020 10-Q
17 04-23-2020 03-31-2020 10-Q
18 02-06-2020 12-31-2019 10-K
19 10-22-2019 09-30-2019 10-Q
20 07-24-2019 06-30-2019 10-Q
21 04-24-2019 03-31-2019 10-Q
22 02-06-2019 12-31-2018 10-K
23 10-23-2018 09-30-2018 10-Q
24 07-24-2018 06-30-2018 10-Q
25 04-24-2018 03-31-2018 10-Q
26 02-01-2018 12-31-2017 10-K
27 10-24-2017 09-30-2017 10-Q
28 07-25-2017 06-30-2017 10-Q
29 04-25-2017 03-31-2017 10-Q
30 02-02-2017 12-31-2016 10-K
31 10-26-2016 09-30-2016 10-Q
32 07-21-2016 06-30-2016 10-Q
33 04-21-2016 03-31-2016 10-Q
34 02-03-2016 12-31-2015 10-K
35 10-21-2015 09-30-2015 10-Q
36 07-24-2015 06-30-2015 10-Q
37 04-24-2015 03-31-2015 10-Q
38 02-04-2015 12-31-2014 10-K
39 10-22-2014 09-30-2014 10-Q
40 07-23-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

will-earnings-cheer-continue-to-buoy-markets-apple-amazon-pfizer-coinbase-lead-flurry-of-q1-reports-this-week
Will Earnings Cheer Continue To Buoy Marke...
04/29/2024 05:51:21

With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and...

barclays-maintains-equal-weight-on-biogen-lowers-price-target-to-200
Barclays Maintains Equal-Weight on Biogen,...
04/25/2024 18:02:40

Barclays analyst Carter Gould maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and lowers the price target from $215 to $200.

these-analysts-revise-their-forecasts-on-biogen-after-q1-results
These Analysts Revise Their Forecasts On B...
04/25/2024 12:53:14

meta-platforms-to-rally-around-14-here-are-10-top-analyst-forecasts-for-thursday
Meta Platforms To Rally Around 14%? Here A...
04/25/2024 12:44:41

wedbush-maintains-neutral-on-biogen-raises-price-target-to-215
Wedbush Maintains Neutral on Biogen, Raise...
04/25/2024 12:33:01

Wedbush analyst Laura Chico maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $213 to $215.

hc-wainwright--co-maintains-buy-on-biogen-lowers-price-target-to-300
HC Wainwright & Co. Maintains Buy on Bioge...
04/25/2024 11:53:17

HC Wainwright & Co. analyst Andrew Fein maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $325 ...

needham-reiterates-buy-on-biogen-maintains-294-price-target
Needham Reiterates Buy on Biogen, Maintain...
04/25/2024 09:33:02

Needham analyst Ami Fadia reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $294 price target.

biogeneisais-popular-alzheimers-drug-leqembi-is-seeing-slow-adoption---heres-why
Biogen/Eisai's Popular Alzheimer's Drug Le...
04/24/2024 18:23:08

Discover the challenges facing Leqembi, the first Alzheimer's drug shown to slow progression. Skepticism among doctors and ...

treasury-yields-rise-tesla-jumps-on-cheaper-model-pledge-yen-plummets-to-34-year-lows-whats-driving-markets-wednesday
Treasury Yields Rise, Tesla Jumps On Cheap...
04/24/2024 17:40:39

Rising Treasury yields have investors cautious despite positive news from the earnings season. The yield on the long-dated 3...

biogens-leqembi-commercial-ramp-up-modest-but-up-ticking-reports-mixed-bag-q1-earnings
Biogen's Leqembi Commercial Ramp-Up Modest...
04/24/2024 16:12:52

Biogen reports Q1 results: adjusted EPS $3.67 (beat consensus), sales $2.29 billion (missed consensus). Leqembi launch uptake t...

needham-reiterates-buy-on-biogen-maintains-294-price-target
Needham Reiterates Buy on Biogen, Maintain...
04/24/2024 12:34:17

Needham analyst Ami Fadia reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $294 price target.

biogen-reaffirms-2024-adjusted-eps-guidance-of-1500-1600-representing-eps-growth-of-approximately-5-versus-2023-at-the-mid-point-versus-consensus-of-1548
Biogen Reaffirms 2024 Adjusted EPS Guidanc...
04/24/2024 10:53:30

Continue to expect total revenue to decline by a low- to mid-single digit percentage vs. 2023 and expect core pharmaceutical ...

biogen-q1-2024-adj-eps-367-beats-344-estimate-sales-2291b-miss-2311b-estimate
Biogen Q1 2024 Adj EPS $3.67 Beats $3.44 E...
04/24/2024 10:49:10

Biogen (NASDAQ:BIIB) reported quarterly earnings of $3.67 per share which beat the analyst consensus estimate of $3.44 by 6.69 ...

nasdaq-futures-get-a-lift-from-tesla-texas-instruments-earnings-analyst-points-to-key-catalyst-for-boosting-rally
Nasdaq Futures Get A Lift From Tesla, Texa...
04/24/2024 10:37:30

Nasdaq and S&P 500 futures signaled a higher open on Wednesday, thanks to upbeat guidance from EV giant Tesla, Inc. (NASDAQ...

can-magnificent-7-help-script-market-turnaround-earnings-pick-up-pace-with-microsoft-meta-alphabet-and-tesla-expected-this-week
Can Magnificent 7 Help Script Market Turna...
04/21/2024 21:45:15

Corporate profit growth rose in Q3 2023 and is expected to continue in Q1.

oppenheimer-maintains-outperform-on-biogen-lowers-price-target-to-270
Oppenheimer Maintains Outperform on Biogen...
04/19/2024 14:53:00

Oppenheimer analyst Jay Olson maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $290 to $270.

wedbush-maintains-neutral-on-biogen-lowers-price-target-to-213
Wedbush Maintains Neutral on Biogen, Lower...
04/17/2024 16:56:02

Wedbush analyst Laura Chico maintains Biogen (NASDAQ:BIIB) with a Neutral and lowers the price target from $245 to $213.

b-of-a-securities-maintains-neutral-on-biogen-lowers-price-target-to-260
B of A Securities Maintains Neutral on Bio...
04/12/2024 12:00:17

B of A Securities analyst Geoff Meacham maintains Biogen (NASDAQ:BIIB) with a Neutral and lowers the price target from $280 ...

where-biogen-stands-with-analysts
Where Biogen Stands With Analysts
04/11/2024 17:01:01

jp-morgan-maintains-neutral-on-biogen-lowers-price-target-to-240
JP Morgan Maintains Neutral on Biogen, Low...
04/11/2024 12:49:29

JP Morgan analyst Chris Schott maintains Biogen (NASDAQ:BIIB) with a Neutral and lowers the price target from $270 to $240.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION